Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TT-OAD2 is a non-peptide agonist of glucagon-like peptide-1 (GLP-1) receptor (EC50: 5 nM), with the potential for diabetes treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | TT-OAD2 is a non-peptide agonist of glucagon-like peptide-1 (GLP-1) receptor (EC50: 5 nM), with the potential for diabetes treatment. |
Targets&IC50 | GLP1 receptor:(EC50)5 nM |
In vitro | In HEK293A cells, TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner [1]. |
In vivo | In male human GLP-1 receptor knock-in and knockout mice, TT-OAD2 (3 mg/kg; intravenous injection)treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1]. |
Molecular Weight | 929.75 |
Formula | C50H49Cl4N3O6 |
CAS No. | 2382719-60-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TT-OAD2 2382719-60-8 Others TTOAD2 TT-OAD-2 TT OAD2 inhibitor inhibit